We’re pleased to announce our paper on Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial , has been published in the Journal of Infection and is now available to read online.
Here is the link to Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial
Working on this study has been a privilege for the PHARMExcel team.
Congratulations to the amazing team and a huge thank you to all the participants who made it possible.
The Lancet: The safety and immunogenicity data from the UK’s Covboost trial.
